Cogent Biosciences to Participate in the Guggenheim Healthcare Innovation Conference

Employee inducement awards include options on 22,000 shares and 16,500 restricted stock units, subject to vesting.

Rhea-AI Summary

Cogent Biosciences (Nasdaq: COGT) will participate in a fireside chat at the Guggenheim Healthcare Innovation Conference on November 10, 2026. The Boston session begins at 7:30 a.m. ET, with a live webcast and a replay available through the company’s website.

Separately, on October 26, 2026, the compensation committee approved inducement awards for six new employees: options to purchase 22,000 shares and 16,500 restricted stock units. Both awards vest over four years, subject to continued employment. The options have a 10-year term and an exercise price equal to the stock’s closing price on the grant date.

Positive

• None.

Negative

• Minor point. Forward-looking: it has not happened yet and may not happen.Inducement awards covering 22,000 stock options and 16,500 restricted stock units create potential shareholder dilution.

Key Figures

Employees receiving awards: 6 employees Options granted: 22,000 shares Restricted stock units granted: 16,500 RSUs +3 more

Employees receiving awards

6 employees

Inducement grants

Options granted

22,000 shares

Aggregate nonqualified options

Restricted stock units granted

16,500 RSUs

Aggregate inducement awards

Option term

10 years

Each option

Option vesting

4 years; 25% at 1 year, remainder over 36 months

Subject to continued employment through vesting dates

RSU vesting

4 years

Annual equal installments, subject to continued employment

Key Terms

restricted stock units, tyrosine kinase inhibitor

2 terms

restricted stock units financial

"16,500 restricted stock units (RSUs)"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

tyrosine kinase inhibitor medical

"a selective tyrosine kinase inhibitor"

A tyrosine kinase inhibitor is a type of drug that blocks specific proteins in cells that act like on/off switches for growth and survival signals, often used to stop cancer cells from multiplying. For investors, these drugs matter because their clinical trial results, regulatory approvals, safety profiles, and patent status drive sales potential and company valuation—think of them as precision tools whose effectiveness and market exclusivity determine commercial success.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

WALTHAM, Mass. and BOULDER, Colo., Oct. 27, 2026 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced its participation in a fireside chat at the Guggenheim 3rd Annual Healthcare Innovation Conference in Boston on Tuesday, November 10, 2026 at 7:30 a.m. ET.

A live webcast can be accessed on the Investors & Media page of Cogent’s website at https://investors.cogentbio.com/events. A replay will be available approximately two hours after the completion of the event and will be archived for up to 30 days.

Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Cogent also announced today that on October 26, 2026, the Compensation Committee of Cogent’s Board of Directors, made up entirely of independent directors, approved the grants of “inducement” equity awards to six new employees under the company’s 2020 Inducement Plan with grant dates of October 26, 2026. The awards were approved in accordance with Listing Rule 5635(c)(4) of the corporate governance rules of the Nasdaq Stock Market. The employees received, in the aggregate, (i) nonqualified options to purchase 22,000 shares of Cogent common stock and (ii) 16,500 restricted stock units (RSUs). Each option has a 10-year term, an exercise price equal to the closing price of Cogent’s common stock on the grant date, and a 4-year vesting schedule with 25% vesting on the 1-year anniversary of the grant date and the remainder vesting in equal monthly installments over the subsequent 36 months, provided such employee remains employed through each such vesting date. The RSUs vest annually in equal installments over 4 years from the grant date, provided such employee remains employed through each such vesting date. 

About Cogent Biosciences, Inc.
Cogent Biosciences is a biotechnology company focused on developing precision therapies for genetically defined diseases. The most advanced clinical program, bezuclastinib, is a selective tyrosine kinase inhibitor that is designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. KIT D816V is responsible for driving Systemic Mastocytosis, a serious disease caused by unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced Gastrointestinal Stromal Tumors (GIST), a type of cancer with strong dependence on oncogenic KIT signaling. In addition, the Cogent Research Team is developing a portfolio of novel targeted therapies to help patients fighting serious, genetically driven diseases targeting mutations in ErbB2, PI3Kα, KRAS and JAK2. Cogent Biosciences is based in Waltham, MA and Boulder, CO. Visit our website for more information at www.cogentbio.com. Follow Cogent Biosciences on social media: X (formerly known as Twitter) and LinkedIn. Information that may be important to investors will be routinely posted on our website and X.

Contact:
Christi Waarich
Senior Director, Investor Relations
christi.waarich@cogentbio.com
617-830-1653

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How do Cogent Biosciences’ October 26, 2026 employee equity awards vest?

The options vest 25% on the first anniversary of the grant date, with the remainder vesting in equal monthly installments over the subsequent 36 months. The restricted stock units vest annually in equal installments over four years from the grant date. Each vesting installment requires the employee to remain employed through that vesting date.